In a systematic review of cost-effectiveness models in type 2 diabetes, oral and injectable semaglutide were cost effective against other within-class products, with some conflicting results.
In plain wordsA review of cost studies in type 2 diabetes found semaglutide often cost effective against similar drugs, with some conflicting results.
- Peptide
- Semaglutide
- Outcome
- Not applicableCost-effectiveness of semaglutide against other within-class products
- Study
n = 50
- Outcome group
- Cost-effectiveness · Metabolic and weight
Source sentences
At a product level, oral and injectable semaglutide, and empagliflozin, were cost effective against other within-class products. Injectable and oral semaglutide were more frequently found cost effective in these comparisons, with some conflicting results.
1 context sentence(design, population, supporting numbers)
Eligible studies were CEAs using DAM to compare NIADs within the glucagon-like peptide-1 (GLP1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, or dipeptidyl peptidase-4 (DPP4) inhibitor classes with other NIADs within those classes for the treatment of T2DM.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.